Flexion Therapeutics Inc (FLXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Flexion Therapeutics Inc (FLXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH194959D
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Flexion Therapeutics Inc (Flexion) develops and commercializes pain therapies. The company's pipeline is focused on indications that includes osteoarthritis knee pain (repeat administration), osteoarthritis knee synovial inflammation, bilateral knee osteoarthritis pain shoulder and hip osteoarthritis pain and inflammatory conditions. The company's marketed product includes Zilretta which is the first and only extended-release, intra-articular therapy for patients confronting osteoarthritis-related knee pain. Flexion employs its proprietary microsphere technology to combine TA with a PLGA matrix for formulating Zilretta. It offers anti-inflammatory and analgesic therapies for osteoarthritis. Flexion is headquartered in Burlington, Massachusetts, the US.

Flexion Therapeutics Inc (FLXN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Flexion Therapeutics Raises USD20 Million In Series B Financing 11

Flexion Therapeutics Raises Additional USD 13 Million In Series A Financing 12

Licensing Agreements 13

Flexion Therapeutics to Acquire Rights to GQ-203 13

Flexion Therapeutics Enters into Licensing Agreement with Southwest Research Institute 14

Equity Offering 15

Flexion Therapeutics Prices Public Offering of Shares for USD122.4 Million 15

Flexion Therapeutics Raises USD74.5 Million in Public Offering of Shares 17

Flexion Therapeutics Raises USD82.6 Million in Public Offering of Shares 19

Flexion Therapeutics Raises USD98.5 Million in Public Offering of Shares 21

Flexion Therapeutics Completes IPO For USD 74.7 Million 23

Debt Offering 25

Flexion Therapeutics Raises USD201.3 Million in Private Placement of 3.375% Notes Due 2024 25

Acquisition 26

Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 26

Flexion Therapeutics Inc-Key Competitors 27

Flexion Therapeutics Inc-Key Employees 28

Flexion Therapeutics Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Nov 07, 2018: Flexion Therapeutics reports third-quarter 2018 financial results and recent business highlights 30

Aug 07, 2018: Flexion Therapeutics reports second-quarter 2018 financial results and recent business highlights 32

May 08, 2018: Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights 34

Mar 08, 2018: Flexion Therapeutics Reports Full Year 2017 Financial Results 36

Nov 06, 2017: Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights 37

Aug 08, 2017: Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 38

May 04, 2017: Flexion Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 39

Mar 09, 2017: Flexion Reports Year-End 2016 Financial Results 40

Corporate Communications 41

May 07, 2018: Flexion Therapeutics Appoints David Arkowitz As Chief Financial Officer 41

Dec 12, 2017: Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as CMO 42

Dec 11, 2017: Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer 43

Jun 28, 2017: Flexion Therapeutics appoints new senior vice president, general counsel and secretary 44

Apr 07, 2017: Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer 45

Product News 46

07/31/2018: New gene therapy treatment for osteoarthritis 46

07/10/2017: Flexion Therapeutics: Update on FX101 47

Clinical Trials 48

Apr 29, 2018: Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49

List of Figures

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Flexion Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Flexion Therapeutics Raises USD20 Million In Series B Financing 11

Flexion Therapeutics Raises Additional USD 13 Million In Series A Financing 12

Flexion Therapeutics to Acquire Rights to GQ-203 13

Flexion Therapeutics Enters into Licensing Agreement with Southwest Research Institute 14

Flexion Therapeutics Prices Public Offering of Shares for USD122.4 Million 15

Flexion Therapeutics Raises USD74.5 Million in Public Offering of Shares 17

Flexion Therapeutics Raises USD82.6 Million in Public Offering of Shares 19

Flexion Therapeutics Raises USD98.5 Million in Public Offering of Shares 21

Flexion Therapeutics Completes IPO For USD 74.7 Million 23

Flexion Therapeutics Raises USD201.3 Million in Private Placement of 3.375% Notes Due 2024 25

Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 26

Flexion Therapeutics Inc, Key Competitors 27

Flexion Therapeutics Inc, Key Employees 28

Flexion Therapeutics Inc, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Flexion Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17948
Site License
USD 500 INR 35895
Corporate User License
USD 750 INR 53843

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com